PSMA Addition: A randomized phase 3 trial of ARPI +/- 177Lu-PSMA617 in mHSPC 1 PSMA+ PET/CT+ve HSPC showed ⬆️ PFS without OS at this stage (⬆️ cross over). Multiple 1st line options exist (E.g BRCA). Earlier treatment seems effective. Later trials achieved OS. #ESMO25@OncoAlert
Very grateful and honoured. Could not have done this without supervisor Johan Gani and coauthors Jaraspong Vuthiwong and Stewart Whalen. Thank you to the #USANZ25 organisers and to the Australasian Urological Foundation @USANZUrology for supporting this award
The Keith Kirkland Award acknowledges the best presentation of a study with direct clinical impact or related to individual patient care by a SET Urology Trainee at #USANZ25. This year's recipient is @LiangGQu. This prize is supported by the Australasian Urological Foundation.
@LiangGQu presents in the Keith Kirkland and Villis Marshall Session at #USANZ25, comparing presentation, risk factors and urodynamic parameters of detrusor overactivity with detrusor underactivity between age groups.
🌟 Celebrating The Annual Editorial Board Meeting & Current Urology Forum! 🌟
Hosted virtually on Zoom on January 8th, 2025, this event brings together experts from across the globe for insightful discussions in:
🔸 Oncological Urology
🔸 Surgery in Urology
🔸 Urolithiasis and Others in Urology
A huge thank you to our speakers:
@Nolazco_JI, @lanboandbio, @LiangGQu, @kadihasanoglu and many more for their dedication and impactful research!
📢 Don’t miss out—share this with your colleagues and help spread the word!
Plus, find more about our editorial board here: https://t.co/dx1I28dIkT 🌐✨
This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap between the evidence and recommendation strength. https://t.co/c1nnbwewIz @bradspellberg
BCG-unresponsive and BCG-exposed definitions might seem controversial. In this editorial, we tried to be practical and make things easier to understand and remember.
Have a look at the graph & the editorial below👇
https://t.co/8Y6jRVPwuX
Breaking news 👉Finally significantly improved OS with adjuvant pembrolizumab in mRCC #kidneycancer 👉HR: 0.62, 38% reduction in death 👇Oral presentation AbsLBA359👉Terrific data &talk by perpetual practice changer @DrChoueiri . Congrats team. @tompowles1@OncoAlert@Uromigos
It’s very special to be back in SF for #gu24 - this one’s commemorating 20 yrs! Prostate yday, urothelial cancers today, and more to come tmrw!
Special thanks to Bailey, @drMPerera, and Prof Mucci @HarvardChanSPH for their assistance with this important SEER work 💪 ⬇️⬇️⬇️
@AoifeMcvey@LiangGQu@DrEricChung - important work highlighting the unintended impact of gynaecologic mesh controversy for prolapse on the surgical management for female continence, Thanks @wjurol@AustinUrology for supporting our work
Check out our very first episode 'Being frank about haematuria' with our very gracious, knowledgeable (and patient) first guest @Brian_D_Kelly.
https://t.co/ICXjXPakbr
Hi #Medtwitter & Urology friends, we're so excited to invite you to check out our podcast trailer below. It's a short intro to what we're all about & we've also included some of our blooper reel at the end for your enjoyment. #UroSoMe#MorningStream https://t.co/tAdWbKPzmU
Very pleased to see the inaugural @SIU_Journal edition now published! Open access to increase its global reach and relevance 🌏 🙌 Head over to https://t.co/UwwxkWoCvJ to check it out (includes #ICUD@WUOF_uroonc summaries like this👇) @lawrentschuk@damien_bolton
Pleasantly surprised to receive this in the mail today! Thank you @Uroweb@eau_yuo for this Third Prize Best Abstract by a resident (even with everything changing to virtual) ☺️ Grateful for the fantastic mentorship I’ve had with @AustinUrology@Austin_Health
Check this out 👉 a systematic review highlighting the *very* limited number of interventions that reduce cancer care delays/barriers in LMICs. In collaboration with @WHO & @NCIGlobalHealth in @OncJournal#globaloncology https://t.co/bTm2cVhlgW